Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | AKT1 | P31749 | 2/20 | 0.82 |
| ▸ | ESR1 | P03372 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | CDC25A | P30304 | 1/20 | 0.82 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | PRKCG | P05129 | 1/20 | 0.60 |
| ▸ | PRKCB | P05771 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 1/20 | 0.60 |
| ▸ | PRKCH | P24723 | 1/20 | 0.60 |
| ▸ | PRKCI | P41743 | 1/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elaidylphosphocholine SCHEMBL10415339 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Oleylphosphocholine SCHEMBL3332097 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Erufosine SCHEMBL18343547 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL23016704 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| Elaidylphosphocholine SCHEMBL18952927 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL23016878 | 1.00 | LMNA (0.82) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL21094307 | 0.94 | LMNA (0.72) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10937575 | 0.92 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10934199 | 0.92 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL30008220 | 0.92 | LMNA (0.69) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| US-20240122978-A1 | RETROVIRAL VECTOR FOR UNIVERAL RECEPTOR THERAPY | UMOJA BIOPHARMA, INC. | 2024-04-18 | — | — | US | claimed |
| CN-117580614-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| EP-4045663-A2 | RETROVIRAL VECTOR FOR UNIVERAL RECEPTOR THERAPY | Umoja Biopharma, Inc. (US) | 2022-08-24 | — | — | EP | claimed |
| US-20220226103-A1 | INTRAOCULAR LENS HAVING A HAPTIC STRUCTURE WITH A STREAMLINED CROSS-SECTIONAL GEOMETRY | ALCON INC. (CH) | 2022-07-21 | — | — | US | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| EP-1876900-A4 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV COLUMBIA (US) | 2009-06-24 | — | — | EP | claimed |
| CN-101340918-A | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2009-01-07 | — | — | CN | claimed |
| EP-1876900-A2 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | The Trustees of Columbia University in the City of New York (US) | 2008-01-16 | — | — | EP | claimed |
| WO-2006118630-A2 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-11-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | LMNA 4327/4885AKT1 21/4885ESR1 3137/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | LMNA 4190/4885AKT1 3905/4885ESR1 3760/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | LMNA 3156/4885AKT1 6/4885ESR1 1173/4885 |
| US-20240122978-A1 | RETROVIRAL VECTOR FOR UNIVERAL RECEPTOR THERAPY | CD4, HAVCR2, CD40 | LMNA 4119/4885AKT1 3315/4885ESR1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.